(Q38019790)

27 August 2017

title

Radioimmunotherapy for B-cell non-hodgkin lymphomas (English)

1 reference

27 August 2017

Michael Tomblyn

1

1 reference

27 August 2017

publication date

1 July 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

19

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

196-203

1 reference

The radiation biology of radioimmunotherapy

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Experimental therapy of disseminated B-Cell lymphoma xenografts with 213Bi-labeled anti-CD74

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Regulation of CD20 expression by radiation-induced changes in intracellular redox status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900304

10.1177/107327481201900304

21 January 2018

Identifiers

DOI

0 references

1 reference